The Trendlines Group Financial Highlights FY2018

Steve Rhodes
Chairman and CEO

Todd Dollinger Chairman and CEO Haim Brosh Chief Financial Officer

20 February 2019



Agenda

- Corporate highlights
- Financial highlights
- Post FY 2018 developments



Legal disclaimer

Important notice

This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. ("Company") or any of its portfolio companies nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever in Singapore, Israel, the United States or in any other jurisdiction. The summary information herein does not purport to be complete. The information in this presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. The information is subject to change without notice.

The past performance of the Company is not necessarily indicative of its future performance. This presentation may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future results, performance or achievements. Actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors and assumptions, such as known and unknown risks and uncertainties, including those risk factors discussed in our Offer Document dated 16 November 2015 and in our other filings with the SGXNET. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those expressed or implied by the forward-looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this presentation only. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.


None of the Company or any of its respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

Neither this presentation nor any of its contents may be used without the prior written consent of the Company.





11 years of portfolio value expansion



^{*}Portfolio value includes the fair value of investments in portfolio companies accounted for under the equity method



Key financial developments FY 2018

	31 December 2018	31 December 2017	Change	% Change
Portfolio value	US\$ 97.2 million	US\$ 96.8 million	US\$ 0.4 million	N.M.*
Book value	US\$ 86.4 million	US\$ 92.9 million	- US\$ 6.5 million	-7.0%
Current assets	US\$ 11.8 million	US\$ 20.4 million	- US\$ 8.6 million	-42.2%
	FY 2018	FY 2017	Change	% Change
Total expenses	US\$ 8.3 million	US\$ 10.1 million	- US\$ 1.8 million	-17.8%
Net gain (loss)	(US\$ 6.3) million	US\$ 3.9 million	- US\$ 10.2 million	N.M.

^{*}N.M.= not meaningful



Key corporate developments FY 2018

- B. Braun Medical SAS, announced as acquirer of Stimatix GI Ltd.'s assets
- MOU signed with Nutreco NuFrontiers and Sirius VC (Brazil)
- Trendlines Medical Singapore and A*ccelerate signed MOU
- Established 10 new portfolio companies
- 20 portfolio companies completed investments: Two companies from strategic partners (Johnson & Johnson Innovation and Nutreco)



10 companies to watch*

- ApiFix Ltd.
- Arcuro Medical Ltd.
- BioFishency Ltd.
- Fidmi Medical Ltd.
- Gordian Surgical Ltd.

- Leviticus Cardio Ltd.
- OrthoSpin Ltd.
- Saturas Ltd.
- STS Medical Ltd.
- ViAqua Therapeutics Ltd.



^{*}Updated report issued 23 January 2019





















Highlights from the "10 Companies to Watch" report

- ApiFix Ltd. and Gordian Surgical Ltd. completed >275 surgeries and >500 surgeries respectively
- Arcuro Medical Ltd. completed 9 successful first-in-human meniscus repair procedures
- STS Medical Ltd. preparing manufacturing capabilities for first approved product
- Leviticus Cardio Ltd. completed successful first in human cases demonstrating wireless power
- OrthoSpin Ltd. completed US\$3 million investment round led by Johnson & Johnson Innovation.
- ViAqua Therapeutics Ltd. announced Nutreco NuFrontiers and VisVires New Protein investments






Consolidated income statement

Group	
Full Year Ende	d
31 December 2018 31 Dec	ember 2017
/11mmd:4md\	/ A al: 4 al \

	of December 2010 of December 2017		
	(Unaudited) US\$'000	(Audited) US\$'000	Change %
Income:			
Gain (loss) from change in fair value of			
investments in Portfolio Companies	(6,046)	9,399	N.M
Income from services to Portfolio Companies	5,760	4,904	17.46
Group's share of losses of companies accounted		4	
for under the equity method	-	(167)	N.M.
Income from contracted R&D services	476	473	0.63
Financial income	1,248	665	87.51
Other income	360	355	1.41
<u>Total</u> income	1,798	15,629	(88.50)
Expenses			
Operating, general and administrative expenses	6,395	8,579	(25.45)
Marketing expenses	404	354	14.12
R&D expenses, net	1,057	1,111	(4.86)
Financial expenses	428	10	4,180
<u>Total</u> expenses	8,284	10,054	(17.60)
Income (loss) before income taxes	(6,486)	5,575	N.M
Tax benefit (Income tax expenses)	168	(1,643)	(110.22)
Net income (loss)	(6,318)	3,932	N.M



Key value components



^{*} Israeli government loans are non-recourse loans which only come due upon exit events.

^{**} Deferred taxes from unrealized portfolio company valuation profits are offset and paid only upon realization of cash from exits.





Post FY 2018 developments

- Two medical portfolio companies established in Singapore as a result of collaboration agreement between Trendlines Medical Singapore Pte. Ltd., National Healthcare Group, and A*ccelerate
- Management changes for 2019 announced
- Publicized successful first in human case for portfolio company Leviticus Cardio Ltd.'s paradigm-shifting wireless heart pump system











Looking ahead: Trendlines Agrifood Fund

US\$40 million agrifood tech-focused venture fund

- Will employ a blended early/late-stage investment strategy to
 - achieve early exits
 - attain IRR of at least 20%

Singapore Government Support

- Prominent Singapore investment fund committed to invest 25% of fund, up to US\$10 million
- Enterprise Singapore
 - Early-stage companies can access proof-of-concept and proof-of-value funding, up to a total of SGD 750,000 per company at favorable terms
 - Application pending for grant funding for incubator
- SEEDS Capital agreed to co-invest with Fund
 - Initial commitment: SGD 5 million
 - 70% of SEEDS' profits paid to the Fund, increasing Fund yield



Trendlines Group VP
Nitza Kardish, PhD,
will relocate to
Singapore to oversee
and coordinate the
Fund's activities.





Creating and developing companies to improve the human condition

SGX: 42T

OTCQX: TRNLY

+972.72.260.7000 www.trendlines.com









Steve Rhodes, Chairman & CEO steve@trendlines.com

Todd Dollinger, Chairman & CEO todd@trendlines.com

Haim Brosh, Chief Financial Officer haim@trendlines.com

FINANCIAL STATEMENTS AND RELATED ANNOUNCEMENT::FULL YEARLY RESULTS		
Issuer & Securities		
Issuer/ Manager THE TRENDLINES GROUP LTD.		
Securities THE TRENDLINES GROUP LTD IL0011328858 - 42T		
Stapled Security No		
Announcement Details		
Announcement Title Financial Statements and Related Announcement		
Date &Time of Broadcast 20-Feb-2019 18:54:15		
Status New		
Announcement Sub Title Full Yearly Results		
Announcement Reference SG190220OTHREHHZ		
Submitted By (Co./ Ind. Name) Haim Brosh		

Designation

Joint Company Secretary